Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Sold by 272 Capital LP

272 Capital LP reduced its stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 45.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,535,820 shares of the medical instruments supplier’s stock after selling 1,299,121 shares during the period. Harvard Bioscience makes up approximately 2.2% of 272 Capital LP’s portfolio, making the stock its 15th biggest position. 272 Capital LP owned about 3.54% of Harvard Bioscience worth $4,377,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. Corsair Capital Management L.P. purchased a new stake in shares of Harvard Bioscience in the 4th quarter valued at approximately $356,000. Riverwater Partners LLC increased its position in shares of Harvard Bioscience by 14.1% during the first quarter. Riverwater Partners LLC now owns 93,197 shares of the medical instruments supplier’s stock worth $395,000 after acquiring an additional 11,492 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Harvard Bioscience by 38.7% in the first quarter. BNP Paribas Financial Markets now owns 75,970 shares of the medical instruments supplier’s stock valued at $322,000 after acquiring an additional 21,183 shares in the last quarter. AMH Equity Ltd boosted its holdings in Harvard Bioscience by 7.5% in the first quarter. AMH Equity Ltd now owns 2,324,200 shares of the medical instruments supplier’s stock valued at $9,855,000 after purchasing an additional 161,307 shares during the period. Finally, Heartland Advisors Inc. increased its holdings in Harvard Bioscience by 2.6% during the 1st quarter. Heartland Advisors Inc. now owns 889,133 shares of the medical instruments supplier’s stock worth $3,770,000 after purchasing an additional 22,666 shares during the period. Institutional investors and hedge funds own 80.87% of the company’s stock.

Harvard Bioscience Stock Performance

Shares of HBIO opened at $2.64 on Tuesday. Harvard Bioscience, Inc. has a 1 year low of $2.50 and a 1 year high of $5.56. The stock has a market capitalization of $114.66 million, a PE ratio of -13.20 and a beta of 1.30. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.94 and a current ratio of 2.05. The stock has a 50-day simple moving average of $2.97 and a 200-day simple moving average of $3.35.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.06). The firm had revenue of $23.10 million during the quarter, compared to analysts’ expectations of $29.91 million. Harvard Bioscience had a negative net margin of 10.56% and a negative return on equity of 2.70%. On average, analysts predict that Harvard Bioscience, Inc. will post 0.11 earnings per share for the current fiscal year.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.